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Tetrahydrobiopterin (BH4) is an endogenously synthe-
sized cofactor, required for various enzyme activities
and for some less well-defined functions. It is also
required at the cellular level. The known enzymes
that depend on BH4 are phenylalanine hydroxylase
(PAH), tyrosine hydroxylase, tryptophan hydroxylases
1 and 2, all three types of nitric oxide (NO) synthases
(NOS), and glyceryl-ether monooxygenase (GEMO).
At the cellular level, BH4 was found to be a growth or
proliferation factor for Crithidia fasciculata and a
control factor for infectivity of Leishmania major. In
the nervous system, BH4 is a self-protecting factor for
NO or a general neuroprotecting factor via the NOS
pathway, and has dopamine-releasing function. The
major controlling point of BH4 biosynthesis is GTP
cyclohydrolase I (GTPCH) whose expression may be
under control of cytokine induction, and at least in
liver, GTPCH activity is inhibited by BH4 (and
stimulated by phenylalanine) through the GTPCH
feedback regulatory protein (GFRP). With regard to
human disease, BH4 deficiency (Fatypical PKU_) due
to autosomal recessive mutations in all cofactor-
metabolizing enzymes (except sepiapterin reductase)
is described as a cause of hyperphenylalaninaemia
(HPA). Under normal conditions the intracellular BH4
level is thought to play a pivotal role in not only the
regulation of tyrosine and tryptophan hydroxylases,
but also in the initial and rate-limiting steps in the
biosynthesis of the catecholamines and serotonin.
Thus, alterations in BH4 levels result in a disturbance
of biogenic amine metabolism which has been impli-
cated as an aetiological factor in a variety of neuro-
logical disorders. Mutations in the gene for GTPCH
are closely related to Dopa-responsive dystonia
(Segawa disease). This evidence strongly supports the
importance of BH4 and dopaminergic transmission in
dystonia. Alterations in BH4 metabolism have been
observed in several neuropsychiatric diseases, such as
Parkinson disease, familial dystonia, and endogenous
depression, as well as in endothelial dysfunction,
vitiligo, and more recently in pain perception. A
subtype of PAH deficiency has been associated with
BH4-responsiveness and mild or moderate phenyl-
ketonuria (PKU) due to specific mutations in the
PAH gene, offering potential pharmacological treat-
ment with BH4 (sapropterine; Kuvan
R). Biomedical
research on BH4 expanded from the initial investiga-
tions in Fatypical PKU_ patients to neurodegeneration,
pain, vascular-endothelial, and epidermal dysfunction
including diabetes, and other disciplines. Regarding
treatment approaches, the field has been extended
from BH4-cofactor and pharmachaperon treatment to
enzyme replacement and experimental gene therapy.
The International Conference on Tetrahydrobio-
pterin, Phenylketonuria, and Nitric Oxide Synthase
was organized in St. Moritz/Champe´r in Switzerland,
on March 23–28, 2008, and hosted approximately 90
scientists from 15 different countries. More than 50
oral presentations were given and organized in
various sessions including BGenetics and biochemistry
of BH4 metabolism^, BBH4 metabolism and defi-
ciency^, BBH4, GEMO, NOS and endothelial dys-
function^, BPAH, PAH as misfolding disease, and
BH4-responsive PKU/PAH^, and BPKU (and new)
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treatment^. The conference was sponsored by Bio-
marin Pharmaceutical Inc., Asubio Pharma Co., and
Merck Serono SA. Generous sponsor support provid-
ed travelling awards for younger scientists and a
special prize for the best presentation dedicated to
the memory of Professor John Wood who died in 2008.
In addition to the scientific highlights, one of the social
emphases of the program was the traditional Pteridines
Cup which took place on the slopes of Corviglia in the
Alps surrounding St. Moritz (see picture). The next
International Symposium on Pteridines and Folates
will take place from June 7 to 12, 2009, in Jeju, Korea
(http://www.biopku.org/bh42009/).
This issue of JIMD includes selected articles from
the St. Moritz conference.
2 J Inherit Metab Dis (2009) 32:1–2
